Product Images Arzerra

This appears to be a table of data related to a type of treatment called ARZERRA in combination with Chiorambucl, and a separate treatment called Criorambuci. The table includes median "morthe" (which may be an error for "months"), numbers of "ik SRAmARMs", and "Time of Progression-Free Sunvival (Months)." The data suggests that ARZERRA plus Chiorambucl had a lower hazard ratio and significantly better P value compared to Criorambucil. However, without additional context, it is not possible to interpret the data accurately.*

This text is presenting statistical data on the probability of progression-free survival for the drug Arzerra compared to observation. Arzerra had a median of 29-44 months of progression-free survival with a hazard ratio of 0.50 and a p-value of <0.0001. Observation had a significantly lower median of 15.24 months of progression-free survival. The text also includes a number at risk table and a time chart for progression-free survival.*

This appears to be a medication label for a product called "Arzerra" by Novartis. It is a single-use vial for intravenous infusion only and should be diluted prior to administration. The vial contains 100mg of active ingredient (ofatumumab) in 20mg/ml solution. The medication should be stored refrigerated between 2-8°C and should not be frozen. The label also includes manufacturer information and a National Drug Code (NDC) number.*

This is a statistical report on the probability of progression-free survival through a comparison between OFA + FC and FC approaches. The data shows that OFA + FC approach has a longer median progression-free surviving time (28.94 months) than FC approach (18.83 months). The report includes hazard ratio, p-value, as well as the number at risk for each approach. The report also presents a graph depicting the time of progression-free survival in months.*